Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Neuros High Frequency Nerve Block: Pivotal trial started

    Neuros Medical Inc., Cleveland, Ohio Product: Neuros High Frequency Nerve Block, Electrical Nerve Block system Business: Neurology Molecular target: NA Description: Alternating current that delivers high-frequency …

    Published on 2/16/2015
  • OPN-305: Phase I/II started

    Opsona Therapeutics Ltd., Dublin, Ireland Product: OPN-305 Business: Cancer Molecular target: Toll-like receptor 2 (TLR2) Description: Humanized IgG4 mAb against the toll-like receptor 2 (TLR2) Indication: Second-line …

    Published on 2/16/2015
  • ReCell: Phase III started

    Avita Medical Ltd. (ASX:AVH), Perth, Australia Product: ReCell Business: Dermatology Molecular target: NA Description: Autologous cell harvesting device Indication: Treat second degree burns Endpoint: Donor site to …

    Published on 2/16/2015
  • Resolaris: Phase Ib/II started

    aTyr Pharma Inc., San Diego, Calif. Product: Resolaris (Resokine) Business: Musculoskeletal Molecular target: NA Description: Protein therapy based on non-canonical functions of secreted forms of aminoacyl tRNA …

    Published on 2/16/2015
  • Sodium thiosulfate: Phase III ongoing

    Fennec Pharmaceuticals Inc. (TSX:FRX; OTCQB:FENCF), Research Triangle Park, N.C. Product: Sodium thiosulfate (STS) Business: Other Molecular target: Not available Description: Sodium thiosulfate Indication: Prevent …

    Published on 2/16/2015
  • TILs: Phase II start

    Lion Biotechnologies Inc. (OTCQB:LBIO), Woodland Hills, Calif. Product: TILs (LN-144) (formerly Contego) Business: Cancer Molecular target: NA Description: Autologous T cell therapy that utilizes tumor infiltrating …

    Published on 2/16/2015
  • Xarelto rivaroxaban: Phase III started

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Xarelto rivaroxaban (BAY 59-7939) Business: Neurology Molecular target: Factor Xa Description: Direct Factor Xa …

    Published on 2/16/2015
  • ADI-PEG 20: Phase I started

    Polaris Pharmaceuticals Inc., San Diego, Calif. Product: ADI-PEG 20 Business: Cancer Molecular target: NA Description: Arginine deiminase (ADI) formulated with polyethylene glycol Indication: Treat advanced …

    Published on 2/9/2015
  • Aldoxorubicin: Phase III resumed

    CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. Product: Aldoxorubicin (formerly DOXO-EMCH, INNO-206) Business: Cancer Molecular target: DNA Description: 6-maleimidocaproyl hydrazone prodrug of doxorubicin Indication: …

    Published on 2/9/2015
  • ALN-CC5: Phase I/II started

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Product: ALN-CC5 Business: Hematology Molecular target: Complement 5 (C5) Description: RNAi therapeutic targeting complement 5 (C5) Indication: Treat …

    Published on 2/9/2015
  • Alpha galactosidase: Completed Phase I/II enrollment

    Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX), Carmiel, Israel Product: Alpha galactosidase (PRX-102) Business: Endocrine/Metabolic Molecular target: Alpha galactosidase A Description: Plant cell-expressed …

    Published on 2/9/2015
  • AQX-1125: Completed Phase II enrollment

    Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP), Vancouver, B.C. Product: AQX-1125 Business: Pulmonary Molecular target: SH2-containing inositol 5-phosphatase (SHIP) Description: SH2-containing inositol 5-phosphatase (SHIP) …

    Published on 2/9/2015
  • Azedra: Phase II resumed

    Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), Tarrytown, N.Y. Product: Azedra (Ultratrace I-131-MIBG, Ultratrace iobenguane I 131) Business: Cancer Molecular target: Norepinephrine transporter Description: Radiolabeled …

    Published on 2/9/2015
  • Combination neural and mesenchymal stem cell therapy: Pilot trial started

    Novastem, Tijuana, Mexico Stemedica Cell Technologies Inc., San Diego, Calif. Product: Combination neural and mesenchymal stem cell therapy Business: Neurology Molecular target: NA Description: A combination of …

    Published on 2/9/2015
  • DCR-MYC: Phase Ib/II started

    Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA), Watertown, Mass. Product: DCR-MYC Business: Cancer Molecular target: v-myc myelocytomatosis viral oncogene homolog (MYC) (c-Myc) Description: Dicer substrate short interfering…

    Published on 2/9/2015
  • Dutetrabenazine: Completed Phase II/III enrollment

    Auspex Pharmaceuticals Inc. (NASDAQ:ASPX), La Jolla, Calif. Product: Dutetrabenazine (SD-809) Business: Neurology Molecular target: Vesicular monoamine transporter 2 (VMAT2) (SLC18A2) Description: Deuterium-substituted …

    Published on 2/9/2015
  • ELAD system: Completed Phase III enrollment

    Vital Therapies Inc. (NASDAQ:VTL), San Diego, Calif. Product: ELAD system Business: Hepatic Molecular target: NA Description: Human liver cell-based extracorporeal liver assist device (ELAD) Indication: Treat alcohol-…

    Published on 2/9/2015
  • FX006: Phase III started

    Flexion Therapeutics Inc. (NASDAQ:FLXN), Burlington, Mass. Product: FX006 Business: Neurology Molecular target: NA Description: Sustained-release intra-articular formulation of triamcinolone acetonide (TCA) Indication: …

    Published on 2/9/2015
  • ImmunTraCkeR: Clinical trial started

    ImmunID S.A.S., Grenoble, France Product: ImmunTraCkeR Business: Diagnostic Molecular target: NA Description: Multiplex PCR-based test which measures the T cell repertoire diversity using peripheral blood Indication: …

    Published on 2/9/2015
  • IW-2143: Phase Ib started

    Bionomics Ltd. (ASX:BNO; OTCBB:BMICY), Thebarton, Australia Product: IW-2143, BNC210 Business: Neurology Molecular target: Not available Description: Anxiolytic compound Indication: Treat anxiety and depression Endpoint…

    Published on 2/9/2015
  • Ixmyelocel-T: Completed Phase IIb enrollment

    Vericel Corp. (NASDAQ:VCEL), Cambridge, Mass. Product: Ixmyelocel-T (Expanded autologous mixed cell therapy) (formerly Vascular repair cells, Tissue repair cells, Cardiac Repair Cells (CRCs)) Business: Cardiovascular …

    Published on 2/9/2015
  • MCLA-128: Phase I/II started

    Merus B.V., Utrecht, the Netherlands Product: MCLA-128 Business: Cancer Molecular target: Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu); Epidermal growth factor receptor 3 (EGFR3) (HER3) (ErbB3) …

    Published on 2/9/2015
  • NurOwn: Phase II ongoing>=

    BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), New York, N.Y. Product: NurOwn (MSC-NTF cells) (formerly Neurotrophic Factor Cells) Business: Neurology Molecular target: Not applicable Description: Autologous …

    Published on 2/9/2015
  • Olodaterol/tiotropium: Phase III started

    Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Olodaterol/tiotropium Business: Pulmonary Molecular target: Muscarinic receptor; Adrenergic receptor beta 2 (ADRB2) Description: Once-daily fixed-dose combination …

    Published on 2/9/2015
  • Opaxio paclitaxel poliglumex: Phase III ongoing

    CTI BioPharma Corp. (NASDAQ:CTIC; Milan:CTIC), Seattle, Wash. Product: Opaxio paclitaxel poliglumex (CT-2103) (formerly Xyotax) Business: Cancer Molecular target: Tubulin Description: Polyglutamate polymer formulation …

    Published on 2/9/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993